Want to see CLYM full AI Analyst Report?
CLYM Stock Chart & Stats
$16.08
-$0.05(-0.39%)
At close: 4:00 PM EDT
$16.08
-$0.05(-0.39%)
Day’s Range― - ―
52-Week Range$1.64 - $18.33
Previous Close$12.82
Volume1.21M
Average Volume (3M)1.56M
Market Cap
$631.80M
Enterprise Value$811.24M
Total Cash (Recent Filing)$183.12M
Total Debt (Recent Filing)$1.31M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Nov 11, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding57,436,256
10 Day Avg. Volume1,148,934
30 Day Avg. Volume1,562,530
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.97
Enterprise Value/Market Cap1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.93K
Enterprise Value/Ebitda-13.67
Forecast
1Y Price Target
$28.11Price Target Upside74.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.79
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Capitalization And Very Low LeverageExtremely low leverage and a materially larger equity base provide financial flexibility for continued research and development. This capitalization reduces refinancing pressure and gives Climb Bio more capacity to advance its pipeline before potential commercial revenues emerge.
Promising CLYM116 Clinical ProfileThe initial pharmacokinetic and pharmacodynamic results support an extended dosing interval and meaningful biological activity for CLYM116. If sustained in patients, this profile could improve treatment convenience and help differentiate the candidate in IgA nephropathy.
Pipeline Advancement And China CollaborationEntering mid-stage testing in China expands clinical development beyond a single setting and demonstrates execution with a development partner. Progress in a local IgA nephropathy population may broaden Climb Bio's strategic opportunities and support future regional development.
Bears Say
No Commercial RevenueThe absence of revenue means Climb Bio has not yet demonstrated commercial traction or an operating business model that funds itself. Its investment case remains dependent on clinical progress and eventual product approval, leaving near-term financial performance disconnected from pipeline spending.
Persistent And Sizable Net LossesLarge recurring losses show that development spending continues to materially exceed any operating income, with losses still well above the 2023 level. This limits earnings visibility and can pressure future capital allocation as the company advances multiple clinical programs.
Continued Negative Cash FlowOngoing operating and free cash outflows indicate that Climb Bio consumes cash to fund development rather than generating internal resources. The deterioration in free cash flow increases the importance of disciplined spending and may create future financing needs before products reach market.
Climb Bio News
CLYM FAQ
What was Climb Bio’s price range in the past 12 months?
Climb Bio lowest stock price was $1.64 and its highest was $18.33 in the past 12 months.
What is Climb Bio’s market cap?
Climb Bio’s market cap is $631.80M.
When is Climb Bio’s upcoming earnings report date?
Climb Bio’s upcoming earnings report date is Nov 11, 2026 which is in 30 days.
How were Climb Bio’s earnings last quarter?
Climb Bio released its earnings results on Aug 06, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.209 by $0.029.
Is Climb Bio overvalued?
According to Wall Street analysts Climb Bio’s price is currently Undervalued.
Does Climb Bio pay dividends?
Climb Bio does not currently pay dividends.
What is Climb Bio’s EPS estimate?
Climb Bio’s EPS estimate is -0.2.
How many shares outstanding does Climb Bio have?
Climb Bio has 57,436,256 shares outstanding.
What happened to Climb Bio’s price movement after its last earnings report?
Climb Bio reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.209. Following the earnings report the stock price went up 12.269%.
Which hedge fund is a major shareholder of Climb Bio?
Currently, no hedge funds are holding shares in CLYM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Climb Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.11 (74.82% Upside)
$28.11 (74.82% Upside)
Blogger Sentiment
Bullish
CLYM Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
482.01%
12-Months-Change
Fundamentals
Return on Equity
-31.79%
Trailing 12-Months
Asset Growth
28.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Climb Bio
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
CLYM Stock 12 Month Forecast
Average Price Target
$28.11
▲(74.82% Upside)
Technical Analysis
Agenus
―
TuHURA Biosciences
―
Ovid Therapeutics
―
Cognition Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
18.06% Insiders
5.54% Mutual Funds
54.37% Other Institutional Investors
11.63% Public Companies and
Individual Investors